Best Drug Delivery Companies in Germany
The 32 best Drug Delivery companies in Germany in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Topas Therapeutics.
- Global Drug Delivery Market Up $6.3B in 2020 – Growth Driven by COVID-
- Rapid Drug Delivery Solution: Enhance Pharmacy’s Services With Mobile
Ranked: Best Drug Delivery companies in Germany
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Topas Therapeutics Developer of nanoparticle-based therapeutics for immunology disorders | $69M | 63 mo ago | Series B | — | 2016 | WordPressMySQLPHP+7 | 54 patents Targeted nanoparticle delivery systems for antigens and viral vectors in immunotherapy | — |
| 2 | Leon-nanodrugs Developer of technology for manufacturing lipid and polymeric nanoparticles for therapeutics 32Product top 21%Patents top 24%Innovation top 26%Moat top 32% All 10 signals ▾Producttop 21% Patentstop 24% Innovationtop 26% Moattop 32% Fundingtop 39% Talentbottom 49% Globalbottom 40% Techbottom 39% Newsbottom 21% Marketbottom 20% Product: 9 distinct product lines · Company stage: Series D Patents: 93 patents matched (strict assignee match) · 73 filings since 2022 vs 20 in 2017-21 rank vs industry peers · Fliar Intelligence Index 32/100 | $20M | 27 mo ago | Series D | Comelia Beier Co-Founder | 2011 | WordPressMySQLPHP+18 | 93 patents Aseptic small-volume liquid mixing devices for lipid nanoparticle drug formulation | — |
| 3 | Rodos BioTarget Provider of drug delivery platform for the treatment of bacterial infections and viral diseases | $5M | 110 mo ago | Deadpooled | — | 2008 | — | 29 patents Lipid-based nanocarriers for targeted gene and immunotherapy drug delivery to immune cells | — |
| 4 | ProtaGene Provider of drug development services for cell & gene therapeutic services | $5M | 157 mo ago | Series B | — | 2004 | WordPressMySQLPHP+26 | — | — |
| 5 | Pantherna Therapeutics Developer of lipid nanoparticle technologies for mRNA-based therapeutics delivery | $4M | 88 mo ago | Seed | Klaus Giese CEO | 2017 | — | 49 patents Lipid nanoparticle delivery systems for nucleic acid therapeutics and related formulations | — |
| 6 | Lonic Liquid Technologies Provider of ionic liquid & nanotechnology coatings for engineering applications | $2M | 32 mo ago | Funding Raised | Thomas Schubert CEO | 2003 | DrupalPHPSvelte+7 | — | — |
| 7 | Thermosome Developer of targeted tumor therapy combined with immune stimulation for cancer | $2M | 127 mo ago | Seed | Martin Hossann Principal Scientist & Co-Founder | 2014 | — | 42 patents Lipid-based oligoglycerol nanoparticles for pharmaceutical delivery | — |
| 8 | Cutanos Developer of dermal targeted delivery systems for immuntherapies | — | 64 mo ago | Seed | Christoph Rademacher Co-Founder | 2019 | — | — | — |
Top 10 Drug Delivery companies in Germany
#1
Series D · Munich, Bavaria · founded 2011 · 8 employees$20.3Mraised▾
Developer of technology for manufacturing lipid and polymeric nanoparticles for therapeutics. The company’s systems support process development and GMP production of nanoparticles. They engineer technology that aims to redefine precision and performance in nanoparticle production. The company empowers partners to accelerate the development of next-generation therapeutics.
- Aug 2024Series D—
- Apr 2020Series B—
- Jul 2015Series A$20.3M
#2
Funding Raised · Heilbronn, Baden Wurttemberg · founded 2003 · 18 employees$2.3Mraised▾
Provider of ionic liquid & nanotechnology coatings for engineering applications. The products include synthesis, catalysis, analytics, electroplating, biotechnology, sensor applications, and others.
- Mar 2024Grant (prize money)$342K
- Sep 2020Grant (prize money)$243.1K
- May 2020Grant (prize money)$291.3K
- Aug 2017Grant (prize money)$760.2K
#3
Series B · Hamburg, Hamburg · founded 2016 · 14 employees$68.5Mraised▾
Developer of nanoparticle-based therapeutics for immunology disorders. The company's pipeline drug candidates include TPM 203 for pemphigus Vulgaris, TPM 501/502 for celiac disease, and anti-drug immune response.
- Jul 2021Series B$21.3M
- Mar 2021Grant (prize money)$492.1K
- Oct 2020Series B$25.8M
- Apr 2020Grant (prize money)$290.8K
#4
Deadpooled · Hannover, Lower Saxony · founded 2008 · 4 employees$4.7Mraised▾
Provider of drug delivery platform for the treatment of bacterial infections and viral diseases. Offers proprietary TargoSphere technology, a nanocarrier platform to achieve enhanced prophylactic and therapeutic approaches against diseases. Claims that TargoSphere can carry high concentrations of compounds spanning a broad range of sizes and structures of classical small molecule drugs to biomolecules, such as proteins, peptides, and nucleic acids. Currently applies TargoSphere technology for two in-house therapeutic applications Targobiotics, for intracellular treatment of bacterial infections, and Targovir, for the treatment of viral diseases.
- Aug 2017Series A$940.7K
- 2016Series A$368.9K
- Apr 2013Series A$3.4M
#5
Seed · Hennigsdorf, Brandenburg · founded 2017 · 12 employees$4Mraised▾
Developer of lipid nanoparticle technologies for mRNA-based therapeutics delivery. The company focuses on organ-specific and cell-selective delivery and expression of mRNA-based therapeutics. It facilitates precise pharmacological targeting of diverse tissues through tailored adjustment of lipid nanoparticles. The company's technologies guarantee efficient mRNA release in target cells for versatile therapies. The company is open to collaborations with pharmaceutical and biotech companies.
- Jul 2019Seed$4M
#6
Series B · Heilbronn, Baden Wurttemberg · founded 2004 · 55 employees$4.6Mraised▾
Provider of drug development services for cell & gene therapeutic services
- Oct 2013Series B$3.8M
- Aug 2012Seed$857.6K
#7
Seed · Munich, Bavaria · founded 2014 · 17 employees$2.2Mraised▾
Developer of targeted tumor therapy combined with immune stimulation for cancer. The company focuses on a new tumor targeting concept for increased local drug concentrations. This aims to achieve improved clinical treatment efficacy. The company is involved in drug development.
- Apr 2016Grant (prize money)$3.1M
- Apr 2016Seed$2.2M
#8
Seed · Berlin, Berlin · founded 2019 · 9 employees—raised▾
Developer of dermal targeted delivery systems for immunotherapies. The company developed a ligand-based targeted drug delivery system that uses a small molecule ligand, which enables the specific uptake of nanoparticles by Langerhans cells. The delivery platform allows the encapsulation of antigen in or onto targeted nanoparticles which are then incorporated in self-dissolving microneedle patches.
- Jul 2021Seed—
#9
Funding Raised · Berlin, Berlin · founded 2013—raised▾
DendroPharm develops advanced nanocarrier systems for applications in drug delivery. DendroPharm offers custom-made nanocarrier synthesis, formulation development, and joint drug development projects together with regulatory affairs and project management services. The technology is based on bio-compatible dendritic core-multishell nanocarriers. This technology was developed between in the group of Prof. Dr. Rainer Haag at the University of Dortmund and the Freie Universität Berlin.
- 2013Grant (prize money)—
#10
Seed · Bochum, North Rhine Westphalia · founded 2009—raised▾
Soluventis is developing its own Nanocarrier-based therapeutics as well as providing its clients with drug delivery formulation services. Their Nanocarriers are based on a platform technology for drug delivery of nucleic acids and peptides. Soluventis has a portfolio of oncologic siRNAs. The company also provides CDMO services providing formulation, analytical, preclinical and clinical studies.
- Feb 2011Seed—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Drug Delivery coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Drug Discovery is moving in Germany
A read on the academic research around Drug Discovery — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 2,331 Germany-affiliated papers.
- Bayer197
- Heidelberg University120
- Goethe University Frankfurt112
- University of Bonn91
- Technical University of Munich76
- Computational biology21→216
- Chemical space15→101
- Virtual screening2→71
- Small molecule8→75
- Combinatorial chemistry5→62
- Computational biology24→129
- Docking (animal)2→81
- Virtual screening4→75
- In silico5→70
- Small molecule2→49
- Drug development6→36
- Computational biology18→45
- Data science1→23
- Bioinformatics4→22
- Clinical trial1→9
Where drug discovery is researched across Germany
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing drug discovery patents in Germany
Germany drug discovery patent filing is cooling — 114,997 filings from 8,000 assignees (2016–2025), led by Boehringer Ingelheim INT, Merck Patent, BASF SE; annual filings 12806→8163.
- Boehringer Ingelheim INT18121
- Merck Patent16850
- BASF SE16193
- Henkel & KGAA9911
- Bayer Cropscience9015
- Bayer Pharma7348
- Bayer IP6052
- Bayer6040
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.